As an important RNA that can regulate AR/AR-Vs protein expression and recover PCa cell sensitivity to enzalutamide, target KDM4A-AS1 through nucleic acid drugs may significantly benefit CRPC patients. This evidence concerns the gene KDM4A and posterior cortical atrophy.